Caribou Biosciences, Inc. Stock 12‑Month Price Target Raised to $11, Implies 869% Upside

Caribou Biosciences (CRBU) shares hit a record low after the company announced plans to explore strategic options. RBC Capital Markets and Leerink Partners downgraded the biotech firm. The company is based in Berkeley, California.

Caribou Biosciences (CRBU) fell 43% to $0.6430 after halting development of two CAR-T cell therapy programs, citing a difficult financing environment. The company plans workforce reductions and is exploring strategic alternatives, including potential mergers or acquisitions.

U.S. stocks fell Wednesday, with the Dow Jones dropping 350 points. Constellation Brands (STZ) reported better-than-expected Q2 earnings, beating estimates with $3.74 EPS and $2.633B sales. The company also acquired SpikedAde. Meanwhile, Caribou Biosciences (CRBU) shares dropped 47% after announcing strategic alternatives exploration. Commodities and European/Asian markets also declined.

RBC Capital downgraded Caribou Biosciences to Sector Perform with a $1 price target, an 11.9% downside from its Oct 6 close. The move follows Caribou's decision to discontinue its allogeneic CAR-T programs, citing financing challenges. The price target was reduced from $10, reflecting a more cautious outlook on the company's growth.

Caribou Biosciences (CRBU) will discontinue development of its vispa-cel and CB-011 CAR-T cell therapy programs, citing financing challenges. The company is exploring strategic alternatives, including potential mergers or acquisitions, and will reduce its workforce. Caribou had $113.8M in cash as of June 30, 2026, according to the company.

Constellation Brands (STZ) shares fell 5.1% in pre-market trading despite beating Q2 earnings and sales estimates, reporting $3.74 EPS and $2.633B revenue. The company also announced the acquisition of SpikedAde. Caribou Biosciences (CRBU) shares dropped 35.7% after exploring strategic alternatives and discontinuing two cell therapy programs.